Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen
Article first published online: 27 APR 2006
Clinical & Experimental Allergy
Volume 26, Issue 1, pages 50–60, January 1996
How to Cite
MENZ, G., DOLECEK, C., SCHÖNHEIT-KENN, U., FERREIRA, F., MOSER, M., SCHNEIDER, T., SUTER, M., BOLTZ-NITULESCU, G., EBNER, C., KRAFT, D. and VALENTA, R. (1996), Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Clinical & Experimental Allergy, 26: 50–60. doi: 10.1111/j.1365-2222.1996.tb00056.x
- Issue published online: 27 APR 2006
- Article first published online: 27 APR 2006
- Submitted 13 February 1995; revised 19 May 1995; accepted 3 July 1995.
- in vitro;
- in vivo diagnosis of birch pollen allergy;
- skin-prick testing;
- intradermal testing;
- recombinant birch pollen allergen Bet v I
Background Type I allergy represents a severe health problem in industrialized countries where up to 20% of the population suffer froin allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis. leading to death.
Objective The aim of this study was to evaluate recombinant Bet v I, the major birch pollen allergen for in vivo and in vitro diagnosis of birch pollen allergy.
Methods A group of 51 birch pollen allergic patients and eight non-allergic control individuals were tested for birch pollen allergy by skin-prick and intradennal testing, comparing commercial birch pollen extracts with recombinant Bet v I. Quantitative and qualitative serological testing was done with natural and recombinant allergens by radioallergosorbent test (RAST), enzyme-linked immunosorbent assay (ELISA) and immunoblotting.
Results Recombinant Bet v I allowed accurate in vivo and in vitro diagnosis of tree pollen allergy in 49/51 patients tested. No false positive results were obtained in any in vitro assay system (ELISA. Westernblot) or by skin testing (skin-prick, intradermal test) with recombinant Bet v I.
Conclusion Our results document that recombinant Bet v I produced in bacterial expression systems allows accurate in vitro and in vivo diagnosis of birch pollen allergy in > 95% of birch pollen allergic patients.